Indirect Comparison Between Eltrombopag & Romiplostim

An indirect comparison to compare the efficacy of eltrombopag versus romiplostim

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Thrombocytopaenia Blood Platelet Disorders Cytopenia Hematologic Diseases Hemic and Lymphatic Diseases Thrombocytopenia

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

About this study

An indirect analysis was conducted to evaluate the relative efficacy of eltrombopag and romiplostim using placebo as a common comparator

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Adults with ITP
Pre-specified treatment
Prospective clinical studies with at least 10 patients

Exclusion criteria

Adults with ITP for other reasons

Treatment and study plan

eltrombopag

Drug

Eltrombopag & standard of care

Romiplostim

Drug

Romiplostim & standard of care

Placebo

Drug

Placebo & standard of care

Primary outcomes

Durable response: platelet count of >=50 and <400 Gi/L

Time frame: 6 months
Overall response: either a durable response or a transient platelet response

Time frame: 6 months

Sponsors and collaborators

Lead sponsor

GlaxoSmithKline

Industry

Registry information

Official study title

Indirect Comparison of Efficacy of Treatments for Idiopathic Immune Thrombocytopenic Purpura - Review of Platelet Responses and Bleeding Events

Important dates

Study start: 2009
Primary completion: 2009
Study completion: 2009
First posted: Nov 8, 2010
Registry last updated: Jun 7, 2017

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed